BioInvent CEO To Step Down And Seek Scientific Successor
With its focus firmly on oncology, the Swedish biotech, and its outgoing chief, believe the company now needs someone with more scientific skills in the CEO role.
You may also be interested in...
The US FDA has halted the biotech company’s Phase II trial in multiple myeloma, a space that has seen a number of new drugs recently enter the market.
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.